- Home
- CRIS vs CLRB Comparison
CRIS vs CLRB Comparison
Compare CRIS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | CLRB |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 12.8M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRIS | CLRB |
|---|---|---|
| Price | $0.93 | $2.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 453.2K | 118.5K |
| Earning Date | 11-06-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,650,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $7.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $0.77 | $2.45 |
| 52 Week High | $3.55 | $20.60 |
Technical Indicators
Market Signals| Indicator | CRIS | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 36.04 |
| Support Level | $0.82 | $3.15 |
| Resistance Level | $0.96 | $3.26 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 41.71 | 0.00 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.